Canaccord Genuity Downgrades Botanix Pharmaceuticals
Canaccord Genuity has downgraded Botanix Pharmaceuticals from a 'Buy' to a 'Hold' rating.
Stocks · News reference
Secretary Brooke Rollins Posts On X "BIG DAY AHEAD FOR AMERICAN FERTILIZER. Headed to Louisiana, where we will break ground on two major projects bringing critical fertilizer production back to American soil. More American investment. More American production. Lower costs and stronger supply chains for American farmers. Stay tuned."
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Canaccord Genuity Adjusts Price Target on Regeneron Pharmaceuticals
Canaccord Genuity has revised its price target for Regeneron Pharmaceuticals, increasing it from $875 to $922.
UBS Maintains Neutral on CF Industries Holdings, Raises Price Target to $134
UBS Adjusts Price Target on CF Industries Holdings to $134
UBS has revised its price target for CF Industries Holdings, Inc. from $123 to $134 while maintaining a Neutral rating.
Intrepid Potash (IPI) Reports Next Week: Wall Street Expects Earnings Growth
Intrepid Potash is expected to report Q3 2026 earnings on November 3, with consensus estimates of $0.13 EPS (up 18.2% YoY) but revenues declining 7.8% to $43.01 million. The stock carries a Zacks Rank #5 (Strong Sell) with 0% Earnings ESP, making it difficult to predict an earnings beat despite a strong historical track record of beating estimates.
Intrepid Potash Selected for USDA Fertilizer Investment & Expansion Program
Intrepid Potash has been selected as one of eight projects to receive funding through the USDA's Fertilizer Investment & Expansion for Long-Term Domestic Supply (FIELDS) Program.